New analysis by Technical Insights, a business unit of Frost & Sullivan (www.Technical-Insights.frost.com), Emerging Developments in Gene Therapy and DNA Vaccines, shows that the unstoppable innovative talent of the gene therapy community is ironing out the technical challenges facing this market. The study provides an overview of several companies involved in gene therapy R&D, details barriers to commercialization, and provides forecasts for disease sectors that are likely to benefit from this technology.
Technical Insights will hold a conference call at 1:00 p.m. (EDT)/ 10:00 a.m. (PDT) on May 8, 2003 to provide a summary and analysis of the latest developments in gene therapy and DNA vaccines. Those interested in participating in the call should send an email to Julia Paulson at jpaulson@frost.com with the following information for registration:
Full name, Company Name, Title, Contact Tel Number, Contact Fax Number, Email. Upon receipt of the above information, a confirmation/pass code for the live briefing will be emailed to you.
'"/>
Contact: Julia Paulson
jpaulson@frost.com
210-247-3870
Technical Insights
2-May-2003